Demant has finalised the sale of Oticon Medical to Impilo - a Nordic company with vast knowledge and extensive experience in the healthcare sector- for a total consideration of up to DKK 600 million, thereby concluding the process of divesting its Hearing Implants business area.

The finalisation of the agreement allows Demant to further strengthen its commitment to delivering on its strategy by focusing on innovative diagnostic solutions, hearing aid technology and delivering professional, personalised care through its clinic network.

At the same time,itprovides a new path forward for Oticon Medical with a new owner dedicated to further developing and growing the company. This ensures the continuity of Oticon Medical’s business operations, a sustained strong position in the market, continued growthand further investments in future innovation for the benefit of customers and patients.

As part of the agreement, and to ensure business continuity, Demant will support Impilo for a defined period of time, as Oticon Medical is developed into a stand-alone business. These transitional services include jointly developing next-generation products, supplying existing and future sound processors, as well as providing local sales, customer and administrative services until such functions are established in Oticon Medical.

 

 

Back to latest news